ICON Reports Modest Revenue Growth in Second Quarter 2026
The Irish contract research organization posted Q2 revenue of $2.06 billion, up 1.4% sequentially, with adjusted EBITDA margin of 15.9%.
Second Quarter Performance
ICON Public Limited Company, the Dublin-based contract research organization with a market capitalization of approximately $13 billion, reported second quarter 2026 results on July 29, showing modest sequential growth across key metrics.
The company generated revenue of $2,063.5 million for the quarter, representing a 1.4% increase from the first quarter of 2026. Adjusted EBITDA reached $327.2 million, or 15.9% of revenue, marking a 3.0% improvement over the prior quarter. GAAP net income totaled $72.6 million, translating to $0.94 in diluted earnings per share.
Recent Insider Activity
According to MarginX data, recent insider transactions include dispositions and awards involving executives Ronan Martin Murphy and Dr. John Climax. Murphy received an award of 5,005 shares while also disposing of an equal number of shares. Dr. Climax similarly disposed of 5,005 shares during the period.
Industry Engagement Ahead
ICON has a calendar of industry events scheduled for the coming months. The company is slated to present at the Society for Clinical Data Management (SCDM) Annual Conference 2026, running from September 14-17. Additionally, ICON will participate in the World Clinical Biomarkers & CDx Summit on October 5, positioning the firm to showcase its capabilities in clinical data management and biomarker development.
These conference appearances come as the broader market awaits the Federal Open Market Committee's rate decision and economic projections on September 16, which could influence sentiment across the healthcare services sector.
Context
With shares last closing at $163.565, ICON continues to operate as one of the world's leading providers of outsourced drug development services. The sequential revenue growth, while modest, indicates continued demand for clinical research services as pharmaceutical and biotechnology companies advance their development pipelines.
This article was generated by MarginX from public news on 2026-07-29. It is not investment advice.